- Poster presentation
- Open Access
XFM-guided delivery of imaging-visible human mesenchymal stem cells into the pericardial space in a porcine model
© Fu et al; licensee BioMed Central Ltd. 2012
- Published: 1 February 2012
- Pericardial Effusion
- Human Mesenchymal Stem Cell
- Pericardial Space
- Pericardial Adhesion
- Cell Microencapsulation
Transmyocardial delivery of stem cells in the setting of acute myocardial ischemia has shown promise to prevent adverse ventricular remodeling1. However, the efficacy is limited by poor cell retention and low survival rates, even for autologous cells. Intrapericardial delivery of microencapsulated stem cells may offer a local and minimally invasive route to enhance cell survival and retention. In this study, we assess the delivery of human mesenchymal stem cells (hMSCs) in a radiopaque microcapsule to the pericardium using x-ray fused with magnetic resonance imaging (XFM) in a porcine model.
The viability of Ba-encapsulated hMSCs was 94.8±6% two days after encapsulation (Fig.1B). Using XFM (Fig.1C), successful puncture and delivery of BaCaps or Ba-encapsulated hMSCs was achieved in all animals. BaCaps were detected on fluoroscopic and c-arm CT images immediately and one week after delivery (Fig.1D). Whereas BaCaps were free floating immediately after delivery, at one week the BaCaps had consolidated as a pseudo epicardial tissue patch. Cardiac function was maintained 1 week post-delivery (LVEF: 36.8±4% at baseline vs. 41.5±5% at 1 week, n=5). Pericardial adhesions and effusion were absent at one week.
XFM-guided intrapericardial injection of Ba-encapsulated hMSCs was safe and reliable. This approach holds promise for safe delivery of allogeneic cellular therapeutics to the heart in patients without pericardial effusion.
Funding was provided by grants: R21/R33-HL89029, MD-SCRFII-0399 and Siemens healthcare.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.